载体引发或抑制：了解载体引发增强抗多糖抗体对结合疫苗的反应。

Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines.

机构信息

National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, New South Wales, Australia.

National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, New South Wales, Australia; Sydney Medical School, The University of Sydney, New South Wales, Australia.

出版信息

Vaccine. 2014 Mar 14;32(13):1423-30. doi: 10.1016/j.vaccine.2014.01.047. Epub 2014 Jan 31.

DOI:10.1016/j.vaccine.2014.01.047

PMID:24492014

Abstract

INTRODUCTION

With the availability of newer conjugate vaccines, immunization schedules have become increasingly complex due to the potential for unpredictable immunologic interference such as 'carrier priming' and 'carrier induced epitopic suppression'. Carrier priming refers to an augmented antibody response to a carbohydrate portion of a glycoconjugate vaccine in an individual previously primed with the carrier protein. This review aims to provide a critical evaluation of the available data on carrier priming (and suppression) and conceptualize ways by which this phenomenon can be utilized to strengthen vaccination schedules.

METHODS

We conducted this literature review by searching well-known databases to date to identify relevant studies, then extracted and synthesized the data on carrier priming of widely used conjugate polysaccharide vaccines, such as, pneumococcal conjugate vaccine (PCV), meningococcal conjugate vaccine (MenCV) and Haemophilus influenzae type b conjugate vaccines (HibV).

RESULTS

We found evidence of carrier priming with some conjugate vaccines, particularly HibV and PCV, in both animal and human models but controversy surrounds MenCV. This has implications for the immunogenicity of conjugate polysaccharide vaccines following the administration of tetanus-toxoid or diphtheria-toxoid containing vaccine (such as DTP).

CONCLUSION

Available evidence supports a promising role for carrier priming in terms of maximizing the immunogenicity of conjugate vaccines and enhancing immunization schedule by making it more efficient and cost effective.

摘要

简介

随着新型结合疫苗的出现，免疫接种计划变得越来越复杂，这是由于潜在的不可预测的免疫干扰，如“载体引发”和“载体诱导表位抑制”。载体引发是指个体在预先用载体蛋白引发后，对糖结合疫苗的碳水化合物部分产生增强的抗体反应。本综述旨在对载体引发（和抑制）的现有数据进行批判性评估，并构想如何利用这一现象来加强疫苗接种计划。